MediciNova to Present at the LD Micro Main Event XIX Investor Conference

Rhea-AI Summary

MediciNova (NASDAQ: MNOV) will present a corporate overview at the LD Micro Main Event XIX in San Diego on Monday, October 20, 2025 at 1:30 PM PT. Presenters are Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer.

A live webcast will be available via the company's investor relations website and a replay will be archived for 90 days. The presenters will be available for one-on-one meetings during the conference (October 19–22, 2025).

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will present a corporate overview at the LD Micro Main Event XIX Investor Conference. The conference is being held on October 19 – 22, 2025 at the Hotel Del Coronado in San Diego, CA.

Presentation Date:	Monday, October 20, 2025
Time:	1:30pm Pacific Time
Register to view presentation:	Webcast Link

A live webcast of the presentation can be accessed on the investor relations section of the MediciNova website. A replay of the webcast will be archived and available following the event for 90 days.

Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference. 

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT:

David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com

FAQ

When will MediciNova (MNOV) present at LD Micro Main Event XIX?

MediciNova will present on Monday, October 20, 2025 at 1:30 PM PT.

Who will present for MediciNova (MNOV) at the October 2025 conference?

Presenters are Yuichi Iwaki, M.D., Ph.D. (President & CEO) and David H. Crean, Ph.D. (Chief Business Officer).

How can investors watch the MediciNova (MNOV) presentation on October 20, 2025?

Watch the live webcast on MediciNova's investor relations website via the provided webcast link.

Will there be a replay of the MediciNova (MNOV) LD Micro presentation?

Yes. A replay will be archived on the investor relations site and available for 90 days after the event.

Can investors request one-on-one meetings with MediciNova (MNOV) management at the conference?

Yes. Drs. Iwaki and Crean will be available for one-on-one meetings throughout the October 19–22, 2025 conference.

Where and when is the LD Micro Main Event XIX taking place for MediciNova (MNOV)?

The conference runs October 19–22, 2025 at the Hotel Del Coronado in San Diego, CA.